Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort
Authors:
- Consortium on Breast Cancer Pharmacogenomics InvestigatorsCIConsortium on Breast Cancer Pharmacogenomics Investigators
- N. Lynn HenryNHN. Lynn Henry
- Matthew J. SikoraMSMatthew J. Sikora
- 20 January 2009
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 117 (3) , 571-575
Abstract
Women with reduced CYP2D6 activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. We collected hot flash frequency and severity data over 12 months from 297 women initiating tamoxifen. We performed CYP2D6 genotyping using the AmpliChip CYP450 test and correlated inherited genetic polymorphisms in CYP2D6 and tamoxifen-induced hot flashes. Intermediate metabolizers had greater mean hot flash scores after 4 months of tamoxifen therapy (44.3) compared to poor metabolizers (20.6, P = 0.038) or extensive metabolizers (26.9, P = 0.011). At 4 months, we observed a trend toward fewer severe hot flashes in poor metabolizers compared to intermediate plus extensive metabolizers (P = 0.062). CYP2D6 activity may be a modest predictive factor for tamoxifen-induced hot flashes. The presence or absence of hot flashes should not be used to determine tamoxifen’s efficacy.Keywords
This publication has 21 references indexed in Scilit:
- Estrogen Receptor Genotypes Influence Hot Flash Prevalence and Composite Score Before and After Tamoxifen TherapyJournal of Clinical Oncology, 2008
- The Endocannabinoid Anandamide Is a Substrate for the Human Polymorphic Cytochrome P450 2D6The Journal of Pharmacology and Experimental Therapeutics, 2008
- Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 GenotypesJournal of Clinical Oncology, 2007
- Clinical Implications of CYP2D6 Genotypes Predictive of Tamoxifen Pharmacokinetics in Metastatic Breast CancerJournal of Clinical Oncology, 2007
- Tamoxifen, hot flashes and recurrence in breast cancerBreast Cancer Research and Treatment, 2007
- Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot FlashesJournal of Clinical Oncology, 2005
- Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patientsBreast Cancer Research and Treatment, 2005
- CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2005
- Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor ParoxetineJNCI: Journal of the National Cancer Institute, 2003
- Tamoxifen in the Treatment of Breast CancerNew England Journal of Medicine, 1998